C&CURE & ADVANCEMENTS
Cure & Advancements/September 12, 2026/3 min read

Teplizumab Preserves Insulin Production Across Different Genetic Types of Type 1 Diabetes

A detailed analysis of the PROTECT trial shows that teplizumab helped young people produce more of their own insulin and use less injected insulin, regardless of their HLA genetic type. The benefit was real but modest, and everyone still requires insulin therapy.

Research summaryVideo report, corroborated with 1 indexed study

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

  • Teplizumab preserved beta cell function in children and teens with newly diagnosed Type 1 diabetes, helping them retain more of their own insulin production at 78 weeks
  • The benefit worked across all genetic types tested, including different HLA profiles, suggesting the treatment may help a broader population
  • At 78 weeks, people on teplizumab used about 0.17 units per kilogram of body weight less insulin per day and spent approximately 6% more time in their target blood sugar range
  • This is a second look at an existing trial, not new evidence of a cure—all participants still required insulin injections

What the PROTECT Trial Measured

The PROTECT trial enrolled 275 young people, ages 8 to 17, who had recently been diagnosed with Type 1 diabetes. Researchers randomly assigned them to receive either teplizumab or a placebo, given as two 12-day courses through an IV. The trial followed participants for 78 weeks and measured how much insulin their pancreases continued to produce on their own, using a marker called C-peptide.

This latest analysis examined a 'per-protocol' group—participants who completed the study as planned and took their assigned treatment with at least 80% adherence. This stricter look at the data helps researchers understand how well the drug works when people follow the protocol closely.

Teplizumab Slowed Insulin Loss Across Genetic Groups

Type 1 diabetes is linked to specific genes, particularly those known as HLA-DR3 and HLA-DR4. Previous research sometimes showed that genetic differences could affect how treatments work. The PROTECT analysis, however, found that teplizumab preserved beta cell function in participants regardless of which HLA genes they carried.

At 78 weeks, people treated with teplizumab had significantly higher levels of their own insulin production compared to those who received placebo. This benefit held true whether participants carried the HLA-DR3 gene, the HLA-DR4 gene, both, or neither.

Real But Modest Improvements in Daily Life

The study measured practical outcomes that matter to people living with Type 1 diabetes. Those on teplizumab required less injected insulin—about 0.17 units per kilogram of body weight less per day. They also spent roughly 6% more time in their target blood sugar range, the hours when their glucose stayed in a healthy zone without high or low swings.

These improvements are meaningful for daily management but represent modest gains rather than dramatic changes. All participants, including those on teplizumab, still needed insulin therapy throughout the trial.

Understanding What This Means

Teplizumab, sold under the brand name Tzield, works by modifying how the immune system attacks insulin-producing cells. By slowing that attack, it preserves the pancreas's remaining ability to make insulin. This is different from a cure, which would stop or reverse the autoimmune process entirely.

This per-protocol analysis is a deeper look at data from an already-reported trial. It does not represent new evidence or a different outcome—rather, it confirms earlier findings by examining the participants who completed the study as designed. Anyone considering teplizumab should discuss its potential benefits and limitations with their care team, as this treatment is not appropriate for everyone with Type 1 diabetes.

Evidence label

Origin: YouTube / T1D Pulse (Video report). Evidence: Video report, corroborated with 1 indexed study. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

From Type1Cure

Read more of our own writing in Stories

More evidence-labeled coverage across the Type1Cure library.